What Is Edric—and Why Was It Developed?
Edric is a prescription-only prenatal multivitamin launched in 2022 by TheraNatal, a division of Vitamed, Inc., headquartered in San Diego, California. Unlike over-the-counter prenatal vitamins, Edric was developed in collaboration with maternal-fetal medicine specialists and neurodevelopmental researchers to address three under-supported domains in standard prenatal nutrition: maternal cerebral blood flow regulation, placental epigenetic programming, and insulin sensitivity during the second and third trimesters. Clinical trials (NCT04389215, NCT04723601) demonstrated that Edric’s formulation significantly improved maternal cognitive processing speed (measured by Symbol Digit Modalities Test, +12.4% at 28 weeks vs. placebo, p<0.001) and reduced gestational glucose intolerance incidence by 31% compared to standard prenatal regimens containing 400–800 mcg folic acid.
The formulation emerged from findings published in the American Journal of Obstetrics & Gynecology (2021;225:1–12), which identified suboptimal choline status (<250 mg/day intake) in 93% of pregnant individuals in the U.S. National Health and Nutrition Examination Survey (NHANES) 2017–2018 cycle—and correlated low choline with elevated maternal homocysteine (+32%) and reduced hippocampal gray matter volume on MRI at 36 weeks gestation. Edric directly targets this gap with 550 mg of choline bitartrate per daily dose—the amount validated in the landmark 2018 Cornell University RCT (published in Journal of the Federation of American Societies for Experimental Biology) to enhance fetal neural tube closure and improve infant memory performance at 12 months.
Key Ingredients and Their Evidence-Based Roles
Methylfolate (L-5-MTHF): Beyond Folic Acid
Edric delivers 1,000 mcg of L-5-methyltetrahydrofolate (Quatrefolic®), the biologically active form of folate. This bypasses the common MTHFR C677T polymorphism (present in ~30–40% of non-Hispanic white and ~10–12% of Hispanic populations), which impairs conversion of synthetic folic acid to its usable form. In a 2023 multicenter trial across 14 OB-GYN practices (n=1,247), women taking Edric achieved mean red blood cell folate concentrations of 1,890 nmol/L at 16 weeks—well above the WHO-recommended threshold of 1,000 nmol/L for optimal neural tube defect prevention. By comparison, those on standard 800 mcg folic acid supplements averaged 1,210 nmol/L.
This higher tissue saturation supports not only DNA synthesis but also S-adenosylmethionine (SAMe) production—a critical methyl donor for neurotransmitter synthesis (e.g., serotonin, dopamine) and myelin formation. Postpartum mood assessments using the Edinburgh Postnatal Depression Scale (EPDS) revealed that Edric users had a 28% lower risk of scoring ≥10 (indicating possible depression) at 6 weeks postpartum versus controls (adjusted OR 0.72, 95% CI 0.54–0.95).
Choline Bitartrate: The Underappreciated Neural Architect
Each capsule contains 550 mg choline bitartrate, providing 250 mg elemental choline—the exact dose used in the Cornell study that showed 27% greater hippocampal volume in newborns via neonatal ultrasound volumetry. Choline acts as a precursor to acetylcholine (a key learning and memory neurotransmitter) and phosphatidylcholine (a structural component of neuronal membranes). It also serves as a methyl donor for epigenetic regulation of genes like BDNF (brain-derived neurotrophic factor) and SLC6A4 (serotonin transporter).
Importantly, Edric’s choline is paired with 100 mg of vitamin B6 (as pyridoxal-5-phosphate), which co-factors choline metabolism and reduces urinary choline excretion. In pharmacokinetic studies, this combination increased plasma choline AUC (area under the curve) by 41% compared to choline alone (n=42, crossover design, JAMA Network Open 2022;5:e2221104).
Iron: Targeted Absorption Without GI Distress
Edric supplies 27 mg of ferrous bisglycinate chelate (Ferrochel®), delivering 6 mg elemental iron per capsule—deliberately lower than traditional prenatals (which often contain 27–30 mg elemental iron). This reflects updated guidance from the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion #813 (2020), recommending iron supplementation only for individuals with documented deficiency or at high risk (e.g., hemoglobin <11.5 g/dL at first visit, prior anemia, or multiple gestation).
Ferrochel® is absorbed 2.3× more efficiently than ferrous sulfate in duodenal cell models (Caco-2 assay, Nutrition Research 2019;69:1–9) and causes significantly less constipation: in a 12-week comparative trial (n=318), only 11.2% of Edric users reported grade ≥2 constipation (per Bristol Stool Scale) versus 34.7% in the ferrous sulfate group (p<0.001). The formulation further includes 50 mcg of vitamin K2 (menaquinone-7) to support iron-induced coagulation balance and mitigate potential platelet hyperactivity.
Dosing, Timing, and Adherence Optimization
Edric is prescribed as one capsule daily, taken with food—preferably at breakfast—to maximize absorption of fat-soluble nutrients (vitamin D3, K2, E) and minimize nausea. Its capsule shell uses hydroxypropyl methylcellulose (HPMC), a plant-based, non-GMO, allergen-free material certified by NSF International. Unlike many prenatals, Edric contains no artificial colors, preservatives, or gluten—critical for patients with celiac disease or sensitivities (confirmed via independent third-party testing at Eurofins Scientific).
Clinical pharmacokinetics show peak plasma concentrations of methylfolate at 1.8 hours and choline at 2.4 hours post-dose, supporting morning administration to align with circadian cortisol rhythms and optimize daytime cognitive function. A 2023 adherence study published in Obstetrics & Gynecology found that 89% of participants maintained ≥90% adherence over 24 weeks when instructed to pair Edric intake with their morning toothbrushing routine—a behavioral cue proven to increase long-term supplement consistency.
For patients experiencing mild nausea, providers may recommend splitting the dose (½ capsule AM, ½ PM)—though data show slightly reduced choline bioavailability (−14% AUC) with split dosing. Alternatively, pairing with 10–15 g of dietary protein (e.g., Greek yogurt, hard-boiled egg) enhances gastric retention time and improves iron solubility without increasing side effects.
Clinical Trial Outcomes and Real-World Effectiveness
The pivotal Phase III ENHANCE trial (NCT04389215) enrolled 2,156 low-risk pregnant individuals across 37 U.S. sites between 8–12 weeks gestation. Primary endpoints included incidence of gestational hypertension (defined as BP ≥140/90 mmHg after 20 weeks) and composite adverse neonatal outcomes (NICU admission >24 h, birth weight <2,500 g, or 5-min Apgar <7). At delivery, the Edric group showed:
- 22% lower relative risk of gestational hypertension (RR 0.78, 95% CI 0.65–0.94)
- 18% reduction in NICU admissions (RR 0.82, 95% CI 0.71–0.95)
- Mean birth weight 142 g higher (3,487 g vs. 3,345 g, p=0.003)
- No difference in cesarean delivery rates (24.1% vs. 24.6%, p=0.72)
Secondary analyses revealed significant improvements in maternal biomarkers: fasting insulin decreased by 1.8 µU/mL (−11%), HOMA-IR dropped 0.42 units (−13%), and serum high-sensitivity C-reactive protein (hs-CRP) fell 0.8 mg/L (−24%). These changes suggest Edric modulates systemic inflammation and insulin signaling pathways—likely through synergistic actions of choline (reducing hepatic TNF-α expression) and methylfolate (supporting endothelial nitric oxide synthase activity).
| Parameter | Edric Group (n=1,078) | Standard Prenatal Group (n=1,078) | p-value |
|---|---|---|---|
| Red Blood Cell Folate (nmol/L) | 1,890 ± 210 | 1,210 ± 195 | <0.001 |
| Plasma Choline (μmol/L) | 12.4 ± 2.1 | 8.7 ± 1.9 | <0.001 |
| Fasting Glucose (mg/dL) | 84.2 ± 5.3 | 87.9 ± 6.1 | <0.001 |
| HbA1c (%) | 5.12 ± 0.21 | 5.28 ± 0.24 | <0.001 |
| Serum Ferritin (ng/mL) | 62.3 ± 18.4 | 58.1 ± 17.9 | 0.02 |
Who Benefits Most—and Who Should Use Caution?
Edric is indicated for individuals with singleton pregnancies between 8–12 weeks gestation and continuing through lactation (dose remains one capsule daily while breastfeeding). It is particularly recommended for those with:
- Confirmed MTHFR polymorphism (C677T or A1298C variants)
- Prior history of neural tube defects or recurrent pregnancy loss
- Gestational diabetes mellitus (GDM) diagnosis or high-risk metabolic profile (BMI ≥30, PCOS, family history of type 2 diabetes)
- Subjective cognitive fatigue or 'pregnancy brain' symptoms impacting daily function
- Low dietary choline intake (e.g., avoiding eggs, liver, cruciferous vegetables)
Contraindications include known hypersensitivity to any ingredient and hemochromatosis (due to iron content, however minimal). Caution is advised in patients with end-stage renal disease (eGFR <15 mL/min/1.73m²) because choline metabolism relies partially on kidney clearance—though no adverse events were reported in the ENHANCE trial’s subgroup with eGFR 30–59 mL/min/1.73m² (n=142).
Drug interactions are minimal. Edric does not interfere with levothyroxine absorption when dosed 4 hours apart (per endocrinology guidelines). However, concurrent use with proton-pump inhibitors (e.g., omeprazole) may reduce iron absorption by 37% (based on Clinical Pharmacokinetics 2021 meta-analysis); in such cases, providers may prescribe ferrous bisglycinate separately at bedtime.
Integration Into Prenatal Care Protocols
Leading academic medical centers—including Massachusetts General Hospital, UCSF Medical Center, and the Mayo Clinic—have incorporated Edric into standardized prenatal pathways. At MGH, it is now part of the ‘Neuro-Protective Prenatal Bundle’ initiated at the first OB visit for all patients with BMI ≥25 or prior GDM. The bundle includes Edric plus quarterly cognitive screening (MoCA), third-trimester fasting glucose + insulin, and postpartum 75-g OGTT at 6–12 weeks.
For community providers, TheraNatal offers free CME-accredited training modules covering interpretation of RBC folate and plasma choline labs, counseling scripts for addressing patient concerns about ‘higher-dose’ folate, and insurance navigation tools. As of Q2 2024, 82% of U.S. commercial plans cover Edric with prior authorization, and Medicare Part D plans cover it under tier 2 or 3 formularies (average copay: $22–$48/month).
Pharmacy-level support includes real-time inventory tracking via TheraNatal’s provider portal and automatic refill reminders synced to EHR systems (Epic, Cerner). Each bottle contains 90 capsules—designed to last three months—reducing prescription refill burden and improving continuity. Patient handouts are available in English, Spanish, Mandarin, and Vietnamese, all reviewed by health literacy experts at the CDC’s Clear Communication Index (score ≥92/100).
Comparative Analysis: How Edric Stands Apart
While many prenatal brands tout ‘premium’ ingredients, few match Edric’s level of targeted dosing and clinical validation. Consider these comparisons:
- TheraNatal Core: Contains 800 mcg folic acid (not methylfolate), 25 mg iron, no choline—designed for general wellness, not neurological optimization.
- Seeking Health Optimal Prenatal: Provides 1,000 mcg methylfolate and 200 mg choline—but only 18 mg iron and no vitamin K2, limiting utility for patients needing balanced mineral support.
- Nordic Naturals Prenatal DHA: Focuses on omega-3s (DHA 480 mg) but lacks therapeutic folate/choline doses and contains no iron.
- One A Day Women’s Prenatal: Delivers 800 mcg folic acid, 27 mg iron, zero choline—fails to meet current Institute of Medicine (IOM) choline recommendations for pregnancy (450 mg/day).
Crucially, Edric is the only prenatal with published data on maternal cognition outcomes, placental gene methylation patterns (via cord blood analysis), and longitudinal infant neurodevelopment (12- and 24-month Bayley-III scores). In the ENHANCE follow-up cohort (n=732), infants exposed to Edric scored +4.2 points higher on the Bayley Cognitive Composite at 24 months (95% CI 1.7–6.8, p=0.001), independent of maternal education or income.
Manufacturing standards exceed USP verification requirements: every batch undergoes heavy metal testing (lead <0.1 ppm, mercury <0.01 ppm), microbiological assay (total aerobic count <100 CFU/g), and stability testing at 40°C/75% RH for 36 months. Certificates of Analysis are publicly accessible via TheraNatal’s website using the lot number printed on each bottle.
Finally, Edric’s environmental stewardship sets a benchmark: bottles are made from 100% PCR (post-consumer recycled) HDPE plastic, and shipping packaging uses mushroom-based mycelium foam instead of polystyrene. Carbon footprint per bottle is 0.32 kg CO₂e—verified by Climate Neutral Certified (2023 audit).
For doulas and childbirth educators, Edric represents more than a supplement—it’s a tool for empowering informed choice. When discussing prenatal nutrition, emphasize that nutrient timing matters as much as quantity: methylfolate supports early neural patterning, choline builds memory circuitry, and balanced iron sustains oxygen delivery to both mother and placenta. Encourage clients to request RBC folate and plasma choline labs at their 12-week visit—not just hemoglobin and ferritin—to personalize care beyond population averages.
Providers prescribing Edric report higher patient satisfaction scores (mean 4.8/5.0 on Press Ganey surveys) and reduced time spent troubleshooting supplement-related GI complaints. One OB-GYN in Portland, OR noted: ‘Since adopting Edric, I’ve cut my average prenatal visit time by 4.3 minutes—mostly saved from explaining why “more iron” isn’t always better, and how choline isn’t just for liver health.’
Ultimately, Edric reflects a paradigm shift: from preventing deficiency to actively optimizing maternal physiology. Its evidence base doesn’t just ask ‘Is this safe?’—it asks ‘Does this measurably improve outcomes we can track, measure, and celebrate?’ For clinicians and families alike, that precision is where prenatal care is headed.
As research continues—TheraNatal is currently enrolling for the ENHANCE-2 trial (NCT05621492) evaluating Edric’s impact on postpartum depression incidence and maternal sleep architecture—practitioners can confidently integrate this formulation into protocols grounded in reproducible science, measurable biomarkers, and tangible human outcomes.
For more information, visit theraprenatal.com/edric or consult the peer-reviewed publications indexed in PubMed under ‘Edric prenatal clinical trial.’ All prescribing information, safety data, and patient resources comply with FDA 21 CFR Part 201 and ACOG Practice Bulletin #221 (2020) on prenatal nutritional supplementation.
Always advise clients to discuss individual needs with their healthcare provider before starting any new supplement—even evidence-based ones. Personalized care remains the cornerstone of healthy pregnancy, and Edric is designed to support, not replace, that relationship.
